CA2525908A1 - Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases - Google Patents

Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases Download PDF

Info

Publication number
CA2525908A1
CA2525908A1 CA002525908A CA2525908A CA2525908A1 CA 2525908 A1 CA2525908 A1 CA 2525908A1 CA 002525908 A CA002525908 A CA 002525908A CA 2525908 A CA2525908 A CA 2525908A CA 2525908 A1 CA2525908 A1 CA 2525908A1
Authority
CA
Canada
Prior art keywords
die
gew
der
von
das
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002525908A
Other languages
English (en)
French (fr)
Inventor
Gerd Thone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2525908A1 publication Critical patent/CA2525908A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA002525908A 2003-05-22 2004-05-18 Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases Abandoned CA2525908A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10323759A DE10323759A1 (de) 2003-05-22 2003-05-22 Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen
DE10323759.3 2003-05-22
PCT/DE2004/001047 WO2004105777A1 (de) 2003-05-22 2004-05-18 Steinmehl, insbesondere dolomitsteinmehlheilmittel, zur behandlung von kresbserkrankungen

Publications (1)

Publication Number Publication Date
CA2525908A1 true CA2525908A1 (en) 2004-12-09

Family

ID=33441300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002525908A Abandoned CA2525908A1 (en) 2003-05-22 2004-05-18 Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases

Country Status (9)

Country Link
US (1) US20060251738A1 (cg-RX-API-DMAC7.html)
EP (1) EP1628671A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006528210A (cg-RX-API-DMAC7.html)
CN (1) CN1795002A (cg-RX-API-DMAC7.html)
AU (1) AU2004243523A1 (cg-RX-API-DMAC7.html)
CA (1) CA2525908A1 (cg-RX-API-DMAC7.html)
DE (1) DE10323759A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005140098A (cg-RX-API-DMAC7.html)
WO (1) WO2004105777A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122543A1 (de) * 2005-05-18 2006-11-23 Tihomir Lelas Mikronisierte mineralische materialien und deren herstellung
US20070009809A1 (en) * 2005-07-08 2007-01-11 Krekeler Mark P Synthetic Nanoparticle Soil Materials
KR101199897B1 (ko) 2011-11-14 2012-11-09 권태동 천연 광물 및 이의 용해물을 유효성분으로 함유하는 암 예방 및 치료용 조성물
KR101199895B1 (ko) 2011-11-14 2012-11-09 권태동 천연 광물 및 이의 용해물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물
DE102013013029A1 (de) * 2013-08-05 2015-02-05 Ernst Fekete Lobbyist-Zellschutz PNI (Psychoneuroimmunium)
CN104606261B (zh) * 2015-03-05 2018-02-09 潘友长 一种沸石药物组合物及其制备方法和用途
RU2629338C1 (ru) * 2016-08-26 2017-08-28 Алам Джан Фармацевтическая композиция для стабилизации гомеостаза и купирования патологических процессов в организме и инъекционная лекарственная форма этой композиции
KR101996383B1 (ko) 2017-12-01 2019-07-04 (주)카데시인코퍼레이션 퓨리톤을 유효성분으로 포함하는 항암용 조성물
CN108403755A (zh) * 2018-05-03 2018-08-17 北京胜泰生物医药科技有限公司 一种沸石药物的组合、制备及用途
US20230225386A1 (en) * 2021-12-30 2023-07-20 H2 Universe Llc Hydrogen-generating composition for dietary and agricultural applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU200933B (en) * 1988-12-22 1990-09-28 Jozsef Markus Process for producing pharmaceutical composition for profilacting and treating osteoporosis
DE19530882A1 (de) * 1995-08-11 1997-02-13 Thomas Dr Ing Loeser Arzneimittel zur Vorbeugung, Begleittherapie und Heilung von Geschwulstkrankheiten
DE19603477A1 (de) * 1996-01-31 1997-08-07 Klaus Dr Med Reuter Tumormittel
EP0889721B1 (de) * 1996-03-25 2002-04-17 Bauer, Wulf Heilmittel zur äusserlichen anwendung und verwendung einer wässrigen öl-emulsion für ein derartiges heilmittel
DE19750328A1 (de) * 1997-11-13 1999-05-20 Klaus Dr Med Reuter Tumormittel
US6251439B1 (en) * 1998-12-16 2001-06-26 Trustee Of The Dartmouth College Composition and method for reducing the risk of carcinogenesis
AU3164899A (en) * 1999-04-26 2000-11-10 Tihomir Lelas Device for micronizing materials
EP1129715A1 (de) * 2000-02-25 2001-09-05 Werner Dr. Reichen Anwendung von Magnesium, Kalzium und Silizium zur Heilung verschiedener Krankheiten und zum allgemeinen Wohlbefinden
EP1319399A1 (en) * 2000-09-19 2003-06-18 Daiichi Pharmaceutical Co., Ltd. Medicinal composition
JP2003063951A (ja) * 2001-08-23 2003-03-05 Nonogawa Shoji Kk 錠剤及びその製造方法
DE10323758A1 (de) * 2003-05-22 2004-12-16 Bauer, Wulf, Dr. Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen

Also Published As

Publication number Publication date
US20060251738A1 (en) 2006-11-09
JP2006528210A (ja) 2006-12-14
RU2005140098A (ru) 2006-08-10
EP1628671A1 (de) 2006-03-01
DE10323759A1 (de) 2004-12-16
CN1795002A (zh) 2006-06-28
WO2004105777A1 (de) 2004-12-09
AU2004243523A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
Rufli et al. Demodex folliculorum: Zur Ätiopathogenese und Therapie der Rosazea und der perioralen Dermatitis
DE69921662T2 (de) Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose
WO1998031378A1 (de) Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
WO2004105777A1 (de) Steinmehl, insbesondere dolomitsteinmehlheilmittel, zur behandlung von kresbserkrankungen
WO2004105776A1 (de) Heilmittel zur inneren anwendung; insbesondere gegen krebserkrankungen
Salih et al. Cytotoxic effect of Rosmarinus officinalis L. leaf extracts on tumor cell line
EP1719519B1 (de) Nahrungsergänzungsmittelpräparat-Set
EP2229950A1 (de) Verwendung von Pflanzen der Gattung Sideritis und Extrakten daraus zur Behandlung des Aufmerksamkeitsdefizit-Hyperaktivitätssyndroms
AT413262B (de) Resveratrol enthaltende arzneistoffgemische sowie deren verwendung zur herstellung von arzneimitteln
DE102016121540A1 (de) Verwendung von Zusammensetzungen aus Wasser/Alkoholextrakten von Schnittholz kultivierten Fruchtkörpern und Feststoff kultivierten Myzel von Antrodia cinnamomea als Zusätze für Anti-Krebs-Agenzien
DE102012010455A1 (de) Mittel zur Pflege von Hautverletzungen und entzündlichen Hauterkrankungen bei Tieren
Prütting Leben als Schaden—Ein Grundsatzstreit um zulässige Parameter schadensrechtlicher Haftungsausfüllung.
DE19633968C2 (de) Abführmittel
EP1354591B1 (de) Topische Zusammensetzung enthaltend Rauchagglomerate
Weberpals Associations between-blocker exposure and cancer prognosis: the role of immortal time bias and analytical approaches in pharmacoepidemiological studies on cancer patient survival
Pölcher Ovarialkarzinomrezidiv: Sollte operiert werden oder reicht die medikamentöse Therapie?
Heid et al. Schlaganfallversorgung in der Prähospitalphase
Knüpper Zahnarztpraxis für Kieferorthopädie.
Bode Gesellschaftsvertragliche Zuweisung des Einnahmenoder Werbungskostenüberschusses einer vermögensverwaltenden GbR bei Gesellschafterwechsel während des Geschäftsjahres.
AT255025B (de) Verfahren zur Herstellung von Antibiotika-Derivaten
Rosenberg Das „paradox-abnorme “Elektroenzephalogramm (EEG)
Pace Unterstützungsbypass Dopamin 250 p/min
Dettling Abgabe von Fertigarzneimittelmustern an Apotheker
Käser et al. Burnout bei Lehrerinnen und Lehrern. Eine Evaluation theoretischer Erklärungsmodelle
Pärli et al. Kassenpflichtige Raucherentwöhnung für «kranke» Raucher (Possible Obligation of the Health Insurance to Pay for Smoking Cessation for'Sick'Smokers)

Legal Events

Date Code Title Description
FZDE Dead